Urology

Patients with high-risk upper tract urothelial carcinoma (UTUC) typically undergo radical nephroureterectomy (RNU)…

Patients with low-grade (LG) Ta non-muscle invasive bladder cancer (NMIBC) exhibit a high recurrence rate, while cancer-specific…

According to the European Association of Urology (EAU) Guidelines, tumour size exceeding 2 cm serves as a crucial factor…

Approximately 15–20% of patients who undergo urethroplasty (UP) with buccal mucosa graft (BMG) will suffer urethral stricture recurrence…

PROSTATE-specific membrane antigen (PSMA)-PET imaging can influence decision-making in prostate cancer, improving survival outcomes…

Radiomics has been proven effective for the characterisation of primary prostate cancer (PCa).1,2 However, the limited interpretability of the proposed models represents one of the major limitations in this field.

Renal cell carcinoma (RCC) is the most common malignant kidney tumour, with clear cell RCC (ccRCC) accounting for 70–80% of all cases. Approximately 15–20% of patients have primary metastatic RCC at diagnosis, and 15–20% of those who receive curative treatment for localised tumours will experience recurrence within 5 years of follow-up.

Urothelial carcinoma in situ (CIS) of the bladder is an intra-epithelial, high grade, malignant neoplasm characterised by flat (non-papillary) growth, with high probability of disease progression.